Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax Inc. NVAX, -10.14% said Tuesday that one million doses of its protein-based COVID vaccine Nuvaxovid are now available in the U.K. "With U.K. data showing that people infected with both COVID-19 and the flu are more than five times as likely to die compared to someone with no infection(1) , it is more important than ever to consider any vaccine offered to you by the National Health Service," said Stanley C. Erck, Novavax chief executive, in a statement.

Novavax stock up 4.4% premarket after it says 1 million COVID vaccine doses now available in the U.K.

GAITHERSBURG, Md. , Sept. 27, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that an initial one million doses of Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine are now available for use in the United Kingdom (U.K.).

Novavax Makes One Million Doses of Nuvaxovid™ Available for Use in the United Kingdom

Abbott Labs

AstraZeneca

BioNTech SE

Co-Diagnostics

Pfizer

Valneva SE

As people acclimatize to the new normal, it's time to look at some vaccine stocks to sell. Instead of relying primarily on vaccines and antiviral drugs, the government let people manage infections.

7 Vaccine Stocks to Sell ASAP Now That the ‘Pandemic's Over'

The problem? Novavax arrived late to the market.

Down 85%, Is There Any Hope for This Struggling Vaccine Stock?

At least one Wall Street analyst expects the COVID-19 vaccine producer to underperform.

Novavax Downgraded by JPMorgan Chase. Time to Sell?

Novavax (NVAX) sinks to a new record level 52-week low after analysts at JP Morgan cut the 12-month target price on the stock by more than $100.

Why Novavax (NVAX) Stock Was Down 13% on Thursday

Moderna

Moderna Inc. (NASDAQ: MRNA) and Novavax Inc. (NASDAQ: NVAX) were trading down over 2% and 4%, respectively in the premarket Friday despite both stocks showing signs a bounce could be in the cards.

Pharma Giants Moderna And Novavax Trend Lower In This Pattern: What's Going On? - Moderna (NASDAQ:MRNA)

Novavax has some serious short-term challenges but could still have growth opportunities in the future.

Why Novavax Stock Is Plunging This Week

Novavax stock is trading at a two-year low amid slowly ramping use of its Covid vaccine, dubbed Nuvaxovid, in the U.S. The post Here Are Novavax's U.S. Vaccination Numbers — And They're Bleak appeared first on Investor's Business Daily.

Here Are Novavax's U.S. Vaccination Numbers — And They're Bleak

The biotech's shares are crumbling today following an analyst downgrade.

Why Novavax Stock Hit a Fresh 52-Week Low Today

Shares of Novavax Inc. NVAX, -7.46% slumped 7.1% in morning trading Thursday, to extend their recent plunge toward a near 2 1/2-year low, after J.P. Morgan threw in the towel on the maker of the COVID-19 vaccine Nuvaxovid, citing expectations of more cuts to revenue guidance.

Novavax stock extends plunge after J.P. Morgan turns bearish, on expectations of more guidance cuts

Novavax (NASDAQ: NVAX ) stock fell 6% on Sept. 21, and kept falling overnight, after a JP Morgan Chase analyst cut his price target from over $100/share down to just $27 with an “underperform” rating.

Why Is Novavax (NVAX) Stock Falling Today?

The shares of Novavax, Inc. (NASDAQ:NVAX) are 4.9% lower this morning, last seen trading at $24.60, following a bear note from J.P.

Novavax Stock Slammed With Hefty Price-Target Cut

NVAX is a risk-on stock at a time investors are turning to risk-off assets. This article looks to see if Novavax still presents an opportunity for investors

Novavax Remains a Risk-On Stock in a Risk-Off Market

BioNTech (BNTX), Moderna (MRNA) and Novavax (NVAX) stocks decline 8.6%, 7.1% and 6.5%, respectively.

Vaccine Stocks Down After Biden Says Pandemic is Over

Whether the pandemic is over or not, plenty of people are still looking for protection against COVID-19.

Vaccine Stocks: Down but Not Out?

Johnson & Johnson

The latest pronouncements by the president aren't exactly doing the two healthcare companies any favors.

Why Novavax and Johnson & Johnson Stocks Slipped Today

It's a mixed day for the stock market, but it's not a good day for vaccine stocks. Across the board, these names are getting sold.

Why Are Vaccine Stocks MRNA, PFE, NVAX, BNTX Down Today?

"The pandemic is over. We still have a problem with COVID. We're still doing a low of work on it. But the pandemic is over," Biden said.

Moderna, BioNTech, and Novavax plunge after President Biden says the COVID-19 pandemic 'is over'

Stocks of the three key vaccine makers fell sharply Monday, after President Joe Biden said the pandemic is over, in an interview with "60 Minutes" that aired on Sunday. Moderna Inc. MRNA, -9.41% fell 9.2%, Pfizer Inc. PFE, -1.76% was down 1.7% and its German partner BioNTech SE BNTX, -9.15% was down 8.4%.

Vaccine stocks Pfizer, BioNTech, Moderna and Novavax slide after Biden says pandemic is over

BioNTech SE - ADR (NASDAQ: BNTX), Moderna Inc (NASDAQ: MRNA) and Novavax, Inc. (NASDAQ: NVAX) are all trading lower during Mo

Why BioNTech, Moderna And Novavax Shares Are Diving

Novavax Inc. NVAX, said Friday that Israel has granted an import and use permit for the company's COVID vaccine for use in people aged 12 and older. The vaccine is protein based, using a more traditional technology than the mRNA used in the vaccines developed by Pfizer Inc. PFE, -0.46% and German partner BioNTech SE BNTX, -1.64% and Moderna Inc. MRNA, -2.54%.

Novavax says its COVID vaccine is now available in Israel for use in people aged 12 and older

GAITHERSBURG, Md. , Sept. 16, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Taiwan Food and Drug Administration (TFDA) has granted expanded emergency use authorization (EUA) for Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adolescents aged 12 through 17.

Novavax Nuvaxovid™ COVID-19 Vaccine Receives Expanded Emergency Use Authorization in Taiwan for Use in Adolescents Aged 12 Through 17

The Israeli Advisory Committee on Epidemics has recommended that Nuvaxovid™ be approved for ages 12 and older as a primary series and as a heterologous booster for those previously vaccinated with mRNA vaccines GAITHERSBURG, Md. , Sept. 16, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Israel Ministry of Health has granted an import and use permit which provides individuals aged 12 and older access to the Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a primary series and as a heterologous booster for those previously vaccinated with mRNA vaccines.

Novavax Nuvaxovid™ COVID-19 Vaccine Now Available in Israel for Individuals Aged 12 and Older

Novavax (NVAX) closed the most recent trading day at $32.55, making no change from the previous trading session.

News for Novavax Stock (NVAX)